{{Rsnum
|rsid=6884552
|Gene=SRD5A1
|Chromosome=5
|position=6661853
|Orientation=plus
|GMAF=0.2961
|Gene_s=SRD5A1
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 33.6 | 49.6 | 16.8
| HCB | 59.9 | 38.0 | 2.2
| JPT | 70.8 | 25.7 | 3.5
| YRI | 66.9 | 26.9 | 6.2
| ASW | 59.6 | 33.3 | 7.0
| CHB | 59.9 | 38.0 | 2.2
| CHD | 70.6 | 22.0 | 7.3
| GIH | 54.0 | 38.0 | 8.0
| LWK | 64.5 | 32.7 | 2.7
| MEX | 36.2 | 46.6 | 17.2
| MKK | 67.7 | 27.7 | 4.5
| TSI | 34.3 | 47.1 | 18.6
| HapMapRevision=28
}}{{PMID Auto
|PMID=23499746
|Title=SRD5A1 and SRD5A2 are associated with treatment for benign prostatic hyperplasia with the combination of 5α-reductase inhibitors and α-adrenergic receptor antagonists
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}